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Background: The prevalence of gout is increasing, and most research on the associated burden has focused on
serum urate (sUA) levels. The present study quantifies the impact of the presence of tophi and frequency of acute
gout attacks on health-related quality of life (HRQOL), productivity, and healthcare resource utilization.
Methods: Patients with self-reported gout (n = 620; 338 in US and 282 across France, Germany, and UK) were
contacted based on inclusion in the 2010 US and EU National Health and Wellness Surveys (Kantar Health) and the
Lightspeed Research ailment panel. Respondents were categorized into mutually-exclusive groups based on
number of gout flares experienced in the past 12 months (0/don’t recall, 1–2, 3, 4–5, 6+), current presence of tophi
(none, 1+, or not sure), and sUA level awareness (yes, no). HRQOL (SF-12v2), healthcare provider visits in the last
6 months, and work productivity and activity impairment (WPAI) were compared across groups.
Results: Most patients were males, mean age of 61 years, who reported experiencing at least one acute gout flare
in the past 12 months, and 12.3% (n = 76) reported presence of tophi. Among the 27.7% (n = 172) of patients who
were aware of their sUA levels, higher sUA was associated with more flares and tophi. Decreased HRQOL was
associated with more frequent flares and presence of tophi. In multivariable models predicting outcomes based on
presence of tophi and number of flares, both flares (≥4) and tophi (≥1) were associated with HRQOL decrements
on physical and mental component summary scores and health utilities (all p < 0.05), after adjustment for age,
gender, and time since diagnosis. Flares were also associated with greater activity impairment.
Conclusions: Impairments associated with gout flares and presence of tophi, across patients in the US and EU,
underscore the importance of effective management of this potentially curable condition.
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Gout affects 3.9% of the adult population in the US (8.3
million) [1] and over 1% of the adult population in Ger-
many and the UK [2]. Gout has increased in prevalence
worldwide [3,4] and it is the most common inflamma-
tory arthritis in men [5]. Acute gout manifests when
monosodium urate (MSU) crystallizes and deposits in
joints, bursae or tendon sheaths, and provokes an* Correspondence: amir.goren@kantarhealth.com
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reproduction in any medium, provided the orinflammatory response that causes a typical gout flare.
This flare is characterized by an acute onset (maximum
within 24 hours) of a heavily inflamed and extremely
painful mono- or oligoarthritis which often results in
short-term sick leave [6]. Serum urate (sUA) concen-
tration above the limit of solubility (>6.8 mg/dL/
400 μmol/L) leads to crystal deposition which is a ne-
cessary precursor for this disease, though many with
hyperuricemia will never develop gout [7,8]. Gout
patients whose sUA is maintained below 6 mg/dL
(360 μmol/L) over time can expect to remain flare freeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agement of gout [9-12]. Higher sUA levels predict
more flares and development of tophi [2,13-16], and
maintaining lower sUA prevents the formation of new
tophi and reduces the size of established ones [17,18].
Gout patients frequently have a number of comorbid-
ities, including obesity, hypertension, high serum lipid
and cholesterol levels, kidney disease, diabetes, and car-
diovascular disease [2,7,19-21]. Due to the rising inci-
dence and prevalence of gout, greater scrutiny has been
directed towards the impact of gout on health-related
quality of life (HRQOL) [22,23], healthcare resource
utilization, and work productivity, a task complicated by
the presence of the other ailments.
Although there is an expanding literature on the hu-
manistic and economic burden of gout, gaps remain.
Much of the current literature linking gout to HRQOL
either relies on data from US veterans [24], patients at a
small number of medical facilities [20], or studies with
small sample sizes [22], while data on work productivity
and activity impairment in gout is very sparse.
The objective of the present study was to better under-
stand the burden associated with signs and symptoms of
gout (namely, tophi and flares) in larger, more diverse,
and more representative samples of patients across the
US and EU than has been reported previously. The sec-
ondary objective was to distinguish the burden of symp-
toms directly attributable to gout from those associated
with comorbid diseases. By highlighting the heterogen-
eity of disease burden within the gout-diagnosed popula-
tion, examining the impact of both tophi and flares
across samples of US and EU patients, this study adds
breadth and specificity to current analyses of gout bur-
den in the literature and can thus contribute to more ef-




Self-reported data were obtained from patients identified
through the US and EU versions of the 2010 National
Health and Wellness Survey (NHWS; Kantar Health,
New York, NY, USA) and the Lightspeed Research (LSR;
New York, NY, USA) ailment panel (used to supplement
respondents not available through NHWS). The NHWS
is a demographically representative, annual cross-
sectional survey of adult respondents (18 years of age
and over), providing self-reported information on treat-
ment, healthcare attitudes and behaviors, patient disease
and demographic characteristics, and health-related out-
comes. NHWS and LSR ailment panel members are
both sourced from a more general LSR panel, whose
members are recruited through opt-in emails, co-
registration with panel partners, e-newsletter campaigns,online banner placements, and both internal and exter-
nal affiliate networks. All panelists explicitly agreed to
become panel members, registered through unique email
addresses, and completed in-depth demographic regis-
tration profiles.
A stratified random sample procedure is implemented
for NHWS so that the final sample mimics the demo-
graphic composition of the country in which it is admi-
nistered, in order to achieve better representativeness.
The US sample is stratified by age, gender, and ethnicity,
and the EU sample is stratified by age and gender. Com-
parisons between the NHWS sample, the US census,
and other national surveys have been made elsewhere
[25,26].
All respondents, from both NHWS and the current
study, gave informed consent, and the study was
approved by the Essex Institutional Review Board (Leba-
non, NJ, USA).
Study population
Panel members reporting a physician diagnosis of gout
were invited to participate via email in an online, self-
administered survey. Out of 1936 patients reporting a
physician diagnosis of gout invited to participate, 747
responded (a 39% response rate), and 620 patients com-
pleted the survey (563 via NHWS), including 338
(54.5%) from the US, 181 (29.2%) from the UK, 85
(13.7%) from Germany, and 16 from France (2.6%).
Measures
Participants completed a web-based questionnaire that
included questions regarding the patient’s gout and sev-
eral validated scales.
Gout characteristics
Information was collected concerning the patient’s gout in-
cluding their most recent serum urate level (sUA: <6 mg/
dL/360 μmol/L, 6 - 8 mg/dL/360-480 μmol/L, or >8 mg/
dL/480 μmol/L), the number of flares in the past 12 months
(don’t recall, 0, 1–2, 3, 4–5, or 6+), the presence of tophi
(not sure, 0, 1, or 2+), and the number of years since they
were diagnosed with gout.
Health-related quality of life
HRQOL was assessed using the Medical Outcomes
Short Form 12 (SF-12v2) questionnaire [27]. This instru-
ment allows for the calculation of physical (PCS) and
mental (MCS) component summary scores. Scores for
the PCS and MCS are normed to the US population
(Mean = 50, SD = 10), with higher scores indicating
greater HRQOL. SF-6D health utilities were also calcu-
lated from responses to the SF-12v2 [28]. Scores for the
SF-6D range from 0.29 (extremely poor health) to 1
(perfect health). Differences in PCS and MCS exceeding
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(MIDs) [29], and 0.03 is the MID for the SF-6D [30].
Resource use
The number of visits to a traditional healthcare provider
in the past six months was assessed.
Work productivity and activity impairment
Work productivity impairments and impairment in daily
activities were assessed using the validated Work Prod-
uctivity and Activity Impairment (WPAI) questionnaire
[31]. Four subscales (absenteeism, presenteeism, overall
work impairment, and activity impairment) were gener-
ated in the form of percentages, with higher values indi-
cating greater impairment. Absenteeism represents the
percentage of work time missed due to health in the past
seven days. Presenteeism represents the percentage of im-
pairment while at work due to health in the past seven
days. Overall work impairment (OWI) is the total per-
centage of work time missed in the last 7 days due to ei-
ther absenteeism or presenteeism. Activity impairment
represents the percentage of impairment during daily ac-
tivities. Only employed respondents provided data on ab-
senteeism, presenteeism, and overall work impairment,
but all respondents provided data on activity impairment.
Statistical analyses
Descriptive statistics and frequency distributions were
undertaken for all variables. Bivariate comparisons on
continuous variables and scales were conducted using t-
tests for comparisons between two groups and ANOVA
for comparisons with three groups or more, followed by
Tukey HSD post hoc tests. Chi-square tests were con-
ducted in the case of categorical variables. Because
symptom levels were collected as categories rather than
exact numbers, correlations between levels of flares,
tophi, and sUA were conducted using Spearman’s rho.
For the purposes of analysis, patients who did not
know whether they had experienced flares were com-
bined into the zero flares group, the assumption being
that any flare that they might have experienced was not
serious enough to have been identified by a physician.
Moreover, analysis of the prevalence of flares revealed
that there were only eight patients (1%) who did not re-
call whether they had flares. Nearly one-third (n = 195,
31%) of respondents were unsure of whether they had
tophi, possibly indicating that they suspected a tophus
but were not certain given the description in the ques-
tionnaire (“Tophi are deposits of crystallized uric acid
that can appear as moveable lumps or whitish nodules”).
Given the substantial number of such patients, it was
deemed prudent to examine them as a separate group.
Multivariable models predicting healthcare resource
use, work productivity, and HRQOL included frequencyof flares in the last 12 months (1–2, 3, 4–5, or 6+, rela-
tive to 0/don’t recall flares), the presence of tophi (1+, or
not sure, relative to 0 tophi), age, gender, and length of
gout diagnosis (in years) as predictors. HRQOL analyses
(MCS, PCS, and SF-6D) were conducted using max-
imum likelihood multiple regression to adjust the MCS
and PCS scores and SF-6D health utilities for the effects
of age, gender, and length of illness. Distributions of
scores were examined and were normally distributed, so
no transformation was applied. Because work productiv-
ity, impairment, and resource utilization are often highly
skewed, we used a generalized linear model (GLM) ap-
proach specifying a negative binomial distribution.
Adjusted logarithmically transformed counts were mod-
eled in the GLM. This approach tested whether the
adjusted transformed counts differed among the groups
while accounting for covariates. In order to make the
results more interpretable, we calculated the antilog of
regression estimates, which yields rate ratio (RR) values.
The rate ratio indicates the number of times greater im-
pairment was for the given group compared with the
reference group (e.g. a rate ratio value of 1.5 would indi-
cate that the mean level of absenteeism for the ≥ 3
flares/year group is 1.5 times that of no flares).
The gout questionnaire did not assess respondents’
comorbid status. However, given the likely contribution
of higher comorbidities to poorer health outcomes
among respondents, comorbid status may be con-
founded with gout flares and tophi in the analyses.
Therefore, a supplementary set of analyses was con-
ducted on the subsample of respondents re-contacted
via the NHWS (n = 563), using the same predictors and
outcomes as described above, but adjusting additionally
for relevant variables available from the NHWS, in
which respondents had participated previously. In par-
ticular, the supplementary models controlled for self-
reported diagnosis with diabetes mellitus, hypertension,
or chronic kidney disease, as well as BMI category (over-
weight, obese, or missing BMI, vs. normal/underweight
as reference). Given the loss of statistical power asso-
ciated with the reduced sample, additional covariates,
and noise introduced by non-contemporaneous mea-
sures assessed at different lags over the course of the
previous year, the supplementary results are reported
only as a footnote to the main analyses, for the purpose
of helping rule out obvious confounds.
Statistical significance was set at p < 0.05 for all hy-
potheses tested. Analyses were performed using SPSS
version 19.0.
Results
Demographics & patient characteristics
The characteristics of the sample are presented in Table 1
and Table 2. The average age was 60.9 years, and
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Most were male (81%), and 38% were employed. Ap-
proximately half were on allopurinol (51%). Thirteen
percent had at least one tophus, and an additional 31%
were unsure of whether they had any tophi. One quarter
(25%) of the sample had been flare-free for the past
12 months, while 38% experienced at least 3 flares in the
same time period.
The subsample of 563 respondents sourced from the
NHWS was similar to the overall sample. Mean age was
61.2 years, 82% were male, and mean duration of gout
was 12 years. The distribution of flares in the past
12 months was the same as in the full sample, and the
proportion of patients reporting tophi was similar (12%
reporting at least 1 tophus, 33% unsure, and 55% report-
ing none). Information about BMI and comorbidities were
also available for this subgroup. Most were obese (53.8%)or overweight (33.9%), with 9.9% underweight or of nor-
mal weight, and 2.3% declining to answer questions about
weight or height. In terms of comorbidities, 5% reported
chronic kidney disease, 26% reported type 2 diabetes, and
63% reported hypertension.
sUA levels
Nearly three quarters of the patients (72%) did not know
their most recent sUA level; of those who knew their
levels (n = 172), 62 (36%) reported sUA below 6 mg/dL/
360/μmol/L. sUA level was positively correlated with
flares experienced in the last 12 months, rs = 0.36, as well
as the number of tophi currently present, rs = 0.37, both
p < 0.001. Tophi were also associated with a higher num-
ber of flares in the last 12 months, rs = 0.29, p < 0.001.
Being unsure of tophi was also associated with higher
sUA, rs = 0.19, p < 0.05, as well as experiencing more fre-
quent flares, rs = 0.20, p < 0.001.
The burden of tophi
Tophi were associated with considerable impairment of
HRQOL. Patients with tophi had lower MCS, PCS, and
SF-6D scores than patients without tophi, while the
scores of those patients unsure of tophi fell in-between
the two other groups. Post hoc tests revealed that both
the tophi group (≥ 1 tophus) and the unsure group had
significantly impaired HRQOL relative to the no tophi
group for all three measures (all p < 0.01). The magni-
tude of these decrements for all three measures
exceeded the commonly accepted MIDs [29,30,32].
Mean values and omnibus tests of statistical significance
are presented in Table 3.
Patients with tophi also had significantly greater im-
pairment of work productivity and activity. Tophaceous
gout was associated with greater absenteeism and over-
all work impairment than both the group without
tophi and the unsure group (both p < 0.05). The pres-
ence of tophi was also associated with significantly
greater impairment in daily activities as compared with
those free of tophi and those unsure of their presence
(both p < 0.01).
The burden of flares
Unadjusted comparisons revealed that HRQOL varied
across the different flare groups, with more flares asso-
ciated with lower HRQOL in a dose-dependent manner.
SF-12 MCS, PCS, and SF-6D health utilities were all sta-
tistically significantly lower in patients with more frequent
flares (all p < 0.001). Although flares were associated with
an apparent numerical increase in work impairment, this
difference did not reach statistical significance within the
employed subsample. However, more frequent flares were
associated with statistically significantly greater impair-
ment of activity in the total sample, with those having the
Table 2 Patient characteristics by tophi and frequency of gout flares

















n % n % n % n % n % n % n % n %
Male 293 84% 154 79% 57 75.0% 127 84% 202 86% 67 74% 66 77% 42 74%
Age M (SD) 61.6 (11.2) 61.1 (11.6) 57.0 (12.6) 62.0 (11.2) 61.3 (11.2) 59.9 (12.9) 59.1 (11.9) 60.5 (11.1)
Length of illness
(years) M (SD)
11.9 (10.4) 11.6 (11.4) 13.3 (10.0) 13.5 (12.0) 12.1 (10.1) 10.6 (10.5) 9.6 (7.6) 13.5 (12.7)
Employed 140 40.1% 69 35.4% 30 39.5% 54 35.8% 94 40.0% 38 41.8% 29 33.7% 24 42.1%
Medication
Allopurinol 182 52.1% 94 48.2% 43 56.6% 91 60.3% 104 44.3% 46 50.5% 48 55.8% 30 52.6%
Febuxostat 8 2.3% 5 2.6% 16 21.1% 4 2.6% 11 4.7% 5 5.5% 4 4.7% 5 8.8%
Probenecid 8 2.3% 4 2.1% 6 7.9% 6 4% 6 2.6% 2 2.2% 2 2.3% 2 3.5%
Benzbromarone 0 0% 0 0% 4 5.3% 0 0% 1 0.4% 1 1.1% 2 2.3% 0 0%
Other 45 12.9% 40 20.5% 12 15.8% 5 3.3% 32 13.6% 74 18.7% 26 30.2% 17 29.8%
none 120 34.4 63 32.3 11 14.5% 48 31.8% 90 38.3% 27 29.7% 17 19.8% 12 21.1%
sUA
Unknown 253 72.5% 152 77.9% 43 56.6% 116 76.8% 168 71.5% 65 71.4% 57 66.3% 42 73.7%
<6 mg/d 45 12.9% 13 6.7% 4 5.3% 23 15.2% 28 11.9% 4 4.4% 5 5.8% 2 3.5%
6-8 mg/dL 40 11.5% 19 9.7% 16 21.1% 6 4% 30 12.8% 18 19.8% 15 17.4% 6 10.5%
>8 mg/dL 11 3.2% 11 5.6% 13 17.1% 6 4% 9 3.8% 4 4.4% 9 10.5% 7 12.3%
Tophi
No tophi - - - - - - 109 72.2% 142 60.4% 44 48.4% 33 38.4% 21 36.8%
Not sure - - - - - - 38 25.2% 65 27.7% 33 36.3% 34 39.5% 25 43.9%
Any tophi - - - - - - 4 2.6% 28 11.9% 14 15.4% 19 22.1% 11 19.3%
Flares
0/don’t recall 109 31.2% 38 19.5% 4 5.3% - - - - - - - - - -
1 to 2 142 40.7% 65 33.3% 28 36.8% - - - - - - - - - -
3 44 12.6% 33 16.9% 14 18.4% - - - - - - - - - -
4 to 5 33 9.5% 34 17.4% 19 25.0% - - - - - - - - - -
6+ 21 6.0% 25 12.8% 11 14.5% - - - - - - - - - -
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impairment of those without. Means and tests of signifi-
cance are presented in Table 4.
Multivariable models
Multivariable models, adjusting for covariates and sim-
ultaneous presence of flares and tophi, showed that
tophi (vs. no tophi) were associated with statistically
significantly lower MCS (p < 0.01) and PCS (p < 0.01)
scores, as was being unsure of the presence of tophi
(both p < 0.01). More frequent flares (≥ 4) were also
associated with lower MCS (p < 0.05); those with 3 or
more flares also had lower PCS scores (p < 0.05). The
adjusted means are presented in Table 5. A similar
pattern emerged in the analyses of health utilities, pre-
sented in Figure 1. As in the analysis of MCS and
PCS scores, both confirmed tophi and being unsure of
tophi were associated with significant impairment ofHRQOL (both p < 0.01). More frequent flares (≥ 3)
were associated with additional decrements in SF-6D
utilities, after adjustment for age, gender, and length of
diagnosis (p = 0.001).
Patients with 1–2 flares in the past year showed signifi-
cant activity impairment compared with those without,
even after adjustment for covariates (p < 0.05), and impair-
ment increased with frequency of flares. Those unsure of
tophi were significantly more impaired in non-work activ-
ities than those without (p < 0.05), though lack of power
prevented this effect from reaching conventional statistical
significance among those with tophi (p = 0.07). The
adjusted means are displayed in Figure 2.
No associations between flares or tophi and measures
of work productivity were observed after adjusting for
covariates, but numbers were small as these analyses
were of necessity limited to the employed 38% of the
sample.
Table 3 Health-related quality of life, work productivity, and resource use by the presence of tophi (unadjusted)
Number of self-reported tophi
No tophi (n = 349) Not sure (n = 195) Any tophi (n = 76)
M SD M SD M SD p
HRQOL
SF-12 MCS 50.07 9.42 46.06 12.12 44.44 12.88 <0.001
SF-12 PCS 42.62 12.30 38.26 11.33 36.90 11.71 <0.001
SF-6D Utility 0.73 0.14 0.66 0.14 0.64 0.16 <0.001
Work Productivity
% Work missed 4.76 17.68 5.28 18.09 8.80 13.65 0.513
% Impairment at work 16.62 23.42 21.36 24.92 37.67 32.13 <0.001
% Overall work impairment 19.43 27.59 24.62 28.36 40.17 34.51 0.002




5.71 6.91 7.02 7.52 7.34 9.26 0.065
Note: MCS: Mental Component Summary; PCS: Physical Component Summary; ER: Emergency Room.
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respondents re-contacted from NHWS, and adjusting for
additional covariates (i.e., BMI, diagnosis with chronic
kidney disease, type 2 diabetes, and hypertension), the
presence of tophi, uncertainty about tophi, and frequent
flares (≥ 4) were all significantly associated with
decreased MCS, PCS, and health utilities, as well as
increased activity impairment. Specifically, having more
than 4 flares in the past year (vs. 0/unknown) was asso-
ciated with lower MCS (p < 0.05), PCS (p < 0.05), SF-6D
(p < 0.05), and activity impairment (p < 0.05) in the sup-
plementary regressions. Likewise, those who were not
sure of whether they had tophi exhibited lower MCS
(p < 0.01), PCS (p < 0.001), SF-6D (p < 0.001), and activ-
ity impairment (p < 0.01) than those with no tophi.
Those reporting at least one tophus (vs. no tophi) alsoTable 4 Health-related quality of life, work productivity, and
Nu
0/don’t recall (n = 151)
M SD
HRQOL
SF-12 MCS 49.91 9.67
SF-12 PCS 43.25 11.61
SF-6D Utility 0.73 0.12
Work Productivity
% Work missed (n = 234) 6.76 23.15
% Impairment at work (n = 229) 14.12 18.35
% Overall work impairment (n = 234) 19.80 26.90
% Activity impairment 28.68 28.42
Resource Use
Number of traditional healthcare provider visits 6.91 8.45
Note: All n = 620 unless otherwise noted. MCS: Mental Component Summary; PCS: Pdemonstrated lower MCS (p < 0.05), PCS (p < 0.01), SF-
6D (p < 0.01), and activity impairment (p < 0.05). Despite
accounting for potential confounders and with reduced
power, almost all results were replicated in terms of mag-
nitude, direction, and significance. The only discrepan-
cies in results were that 3 flares became non-significantly
associated with a health utilities decrement (p = 0.31),
and the associations between 1–3 flares and greater
activity impairment (relative to no flares) fell below
conventional levels of significance (1–2 flares: p = 0.051;
3 flares: p = 0.075).
Comparisons across the spectrum of disease phenotypes
Patients were categorized into three subgroups based on
frequency of flares and the presence of tophi, without re-
gard to treatment; 1) asymptomatic gout (no flares in theresource use by annual gout flares (unadjusted)
mber of self-reported flares in past 12 months
1 to 2 (n = 235) 3 (n = 91) 4 to 5 (n = 86) 6+ (n = 57)
M SD M SD M SD M SD p
49.23 10.30 47.85 10.03 44.66 13.03 44.46 13.43 <0.0001
42.72 12.27 38.16 11.85 37.04 11.40 33.49 9.99 <0.0001
0.72 0.14 0.67 0.15 0.64 0.17 0.61 0.13 <0.0001
5.16 16.23 4.66 17.42 1.85 5.11 8.71 14.99 0.661
21.22 26.72 21.62 27.84 19.26 26.01 33.33 30.60 0.056
23.23 29.80 24.29 30.42 19.93 26.70 36.58 33.32 0.197
36.77 33.39 43.41 34.42 45.58 34.39 54.21 30.29 <0.0001
5.68 6.01 8.29 10.09 8.02 8.76 7.40 6.79 0.032
hysical Component Summary; ER: Emergency Room.
Table 5 Mean MCS and PCS values by flare frequency and
the presence of tophi, adjusted for age, gender, and
length of illness
Number of self-reported flares in past 12 months
0/don’t recall 1 to 2 3 4 to 5 6+
SF-12 MCS
No tophi 50.44 50.32 50.07 47.35 46.84
Not sure 47.20 47.07 46.83 44.11 43.59
1+ tophi 46.86 46.73 46.49 43.77 43.25
SF-12 PCS
No tophi 44.05 43.72 40.26 39.17 36.08
Not sure 41.06 40.73 37.27 36.17 33.09
1+ tophi 40.20 39.87 36.40 35.31 32.23
Note: MCS: Mental Component Summary; PCS: Physical Component Summary.
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as confirmed tophi and ≥ 3 flares in the past year) and 3)
very severe tophaceous gout (defined as confirmed tophi
and ≥ 6 flares in the past year). The groupings were simi-
lar to those employed in a previous study [33]. Both the
severe group (n = 44) and very severe subgroup (n = 11)
had significantly lower SF-6D health utilities than did the
asymptomatic group (both p < 0.01).
The average SF-6D scores of the severe and very severe
gout patients were also compared with the average SF-6D
scores of US patients with other chronic rheumatic dis-
eases. Average SF-6D scores for gout patients who did not
report rheumatoid arthritis (RA), osteoarthritis (OA), or
systemic lupus erythematosus (SLE), and average utilities
of patients with RA, OA, and SLE patients without
comorbid gout were calculated from the 2010 US NHWS.
The means are presented in Figure 3. Independent-sample
t-tests revealed that asymptomatic gout patients hadFigure 1 Mean SF-6D health utilities by flare frequency and the prese
Lower values indicate worse health; error bars represent standard error of t
with lower health utilities relative to no tophi and no flares/don’t recall, reshigher health utilities than all other patient groups (all
p < 0.05). In contrast to the asymptomatic patients,
those in our sample with severe gout had health utilities
similar to the average SLE or RA patient (both p > 0.05),
and significantly worse than the average gout or osteoarth-
ritis patient in the NHWS (p < 0.05). Patients with very
severe gout had significantly lower health utilities than
any comparison group (p < 0.01).
Discussion
This study demonstrates that gout patients from the US
and three EU countries suffer from significantly
decreased HRQOL, with the average patient suffering
decreased mental as well as physical well-being, relative
to population norms. These decrements in HRQOL vary
across the spectrum of clinical phenotypes according to
the presence and frequency of gout symptoms and signs.
Patients with confirmed tophi and more frequent acute
gout attacks had lower HRQOL, and the association be-
tween HRQOL, tophi and flares remained significant
even after accounting for covariates. Impairments were
not limited to HRQOL, and unadjusted comparisons
revealed that patients reporting tophi had greater work
impairment than those without, while more frequent
flares were associated with increased healthcare resource
use. Both flares and tophi were also associated with sig-
nificant impairments in non-work activities in multivari-
able models.
Impairment of the physical components of quality of
life have been found consistently in studies of gout
patients [22,24,34,35], and was notably related to the
burden of symptoms and signs in this sample. Those
with more severe gout had low PCS compared with both
population norms and those gout patients who were freence of tophi, adjusted for age, gender, and length of illness.
he mean. Tophi (1+ or not sure) and flares (4+) are both associated
pectively (all p < 0.05).
Figure 2 Mean overall activity impairment by flare frequency and presence of tophi, after adjusting for age, gender, and length of
illness. Higher values indicate greater impairment; error bars represent standard error of the mean. Those with any flares are significantly more
impaired than those without flares after adjusting for age, gender, and length of illness. Compared with those without tophi, those unsure of
tophi were also more impaired (p < 0.05) and there was a trend for greater impairment among those with tophi (p = 0.07).
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significant, and greater than those which are generally
accepted as being clinically meaningful. These studies
confirm a relationship between symptom load and
HRQOL previously observed in smaller samples of gout
patients in the US [20,35]. The PCS levels in the most
severely affected patients in these studies were compar-
able to those reported in previous studies of patients
with severe symptomatic gout and patients with gout
who had not responded to urate-lowering therapy
[20,35].
Gout patients are known to use more healthcare



























Figure 3 Average health utilities of patients with gout and patients with
taken from 2010 US NHWS (red) and the current study (orange). Error bars repr
tophi is significantly worse than all comparison conditions, p < 0.05. RA: rheumsufferers incurred more costs for medical claims, pre-
scription claims, sick leave, short-term disability, and
worker’s compensation than did other employees [36].
Another database study of gout in the elderly found
higher healthcare resource utilization in gout patients
than in matched controls, which was attributable in part
to having more comorbidities [37]. While comorbid con-
ditions may account for some of the elevated resource
use among gout patients, gout-related healthcare
utilization increases with severity of gout [38]. A study
using the MarketScan database showed that patients
having 3 or more flares per year had more comorbid-











other rheumatic diseases. Average health utilities are unadjusted values
esent standard error of the mean. Mean utility for gout with 6+ flares and
atoid arthritis; OA: osteoarthritis; SLE: systemic lupus erythematosus.
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gout [33]. Administrative claims data also show that
higher sUA is associated not only with a greater number
of flares, but also with higher costs per flare [16,39].
There is evidence that gout affects worker productiv-
ity. A diary study of patients with chronic gout refrac-
tory to conventional urate-lowering therapy found an
average annual workday loss of 25 days [36]. Another
study showed that employees with gout missed 4.56
more days of work per year [40]. Gout symptoms and
signs were also associated with impairment in daily ac-
tivities, although the limited number of patients report-
ing tophi restricted the possibility of detecting activity
impairment associated with tophi over and above the
strong effect of flares. It is important to bear in mind
that these impairments are compared with those of gout
patients who are free of acute symptoms, rather than
those in the population at large. It seems likely that
comparisons between these patients and the general
population would demonstrate larger differences in
HRQOL and impairment of activities. The failure to
demonstrate significant reduction in work productivity
in the gout patients participating in these studies should
not be interpreted as indicating that gout has no effect
on work performance or productivity. The number of
patients in employment in the study was relatively small
and as the average age was 61 years, many are likely to
have been in retirement. A recent diary study documen-
ted productivity impairments due to gout flares [41], a
finding that needs to be confirmed in a larger sample of
employed patients. It is certainly possible, however, that
patients with severe gout lose their jobs or decide to re-
tire as a result of their disease; such loss of productivity
would not be ascertained in a diary study or with the
WPAI questionnaire used in this study.
In the present study, patients who reported symptoms
of inadequately controlled chronic gout (similar to re-
fractory chronic gout), defined here as at least three
flares in the past year and the presence of at least one
tophus, had severely impaired HRQOL, with SF-6D
health utilities 0.13 below those in patients free of tophi
and free of flares for the past 12 months. The magnitude
of these decrements can be placed into context by com-
paring the health utilities of patients with gout across
the spectrum of clinical phenotypes with those reported
by patients with other rheumatic diseases. As indicated
in Figure 3, patients with gout had similar health utilities
to patients suffering from RA or SLE. Those with most
severe gout, characterized by tophi and six or more
flares in the past year, had health utilities that were sig-
nificantly lower than the average for either RA or SLE.
The findings emphasize the importance of seeking to
provide effective treatment for all patients with gout and
particularly those with tophi and frequent flares.Our study has a number of limitations. As in all cross-
sectional analyses based on self-reported patient infor-
mation the data reported may be subject to recall bias
and the ability of the patients to accurately report infor-
mation about their condition. A total of 8 patients did
not recall whether they had flares. While this small
number was not expected to alter results significantly, to
the extent that there were patients with flares in that un-
known group, this would render our results more con-
servative. The survey did not attempt to ascertain the
size or location of tophi, which may be an important de-
terminant of impairment of HRQOL in patients with
tophaceous gout. Although it is likely that comorbid sta-
tus was confounded with tophi/flares in contributing to
poorer health outcomes, controlling for comorbidities
(and BMI) in the current study did not detract from the
overall findings, in spite of the reduced statistical power.
Having tophi and at least four flares in the past year
were still significantly associated with the poorer out-
comes. Patients’ diagnosis with gout was not verified.
Previous studies have, however, shown that a high pro-
portion of self-reported cases of gout meet classification
criteria when assessed by physician, hospital discharge
diagnosis, or use of gout-specific medication [20,42-44].
The generalizability of the findings may be limited by
self-selection of subjects into the survey panel and/or
the survey itself. The relationships between variables
observed are correlations which cannot be deemed to be
causal. Unmeasured variables (such as the number or se-
verity of comorbid conditions) may explain a portion of
the observed effects, although an association between
physical HRQOL and gout symptoms has been observed
after controlling for comorbidities in a previous study
[34]. The comparisons across rheumatic diseases must
be interpreted with caution. No attempt was made to
control for covariates or potential confounders, which
may explain most or all of the observed differences in
health utilities.Conclusions
The impairment of HRQOL in patients with gout
increases with the presence of tophi and the frequency
of flares, even after adjusting for covariates. Gout symp-
toms are also associated with greater impairment in daily
activities. Gout characterized by severe symptoms and
signs (i.e., 3+ flares/year and tophi) imposes a substantial
and clinically meaningful burden on the patient at least
comparable to the impairment of HRQOL associated
with other rheumatic diseases. These findings, across
representative samples of patients in both the US and
EU, highlight the different potential impacts of gouty
tophi and flares and underscore the importance of ef-
fective management of this potentially curable condition.
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